ArticleOrphanet journal of rare diseases2023

Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults.

Robin H Lachmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.